A microvascularized in vitro liver model for disease modeling and drug discovery
Source abstract
Abstract
Abstract Drug discovery for complex liver diseases faces alarming attrition rates. The lack of non-clinical models that recapitulate key aspects of liver (patho)-physiology is likely contributing to the inefficiency of developing effective treatments. Of particular notice is the common omission of an organized microvascular component despite its importance in maintaining liver function and its involvement in the development of several pathologies. Increasing the complexity of in vitro models is usually associated with a lack of scalability and robustness which hinders their implementation in drug development pipelines. Here, we describe a comprehensive liver microphysiological system comprising stellates, liver-derived endothelial cells and hepatocytes conceived within a scalable and automated platform. We show that endothelial cells self-organize in a microvascular network when co-cultured with stellates in a hydrogel. In a tri-culture, hepatocytes polarize accordingly, with a basolateral side facing blood vessels and an apical side facing bile-canaliculi-like structures. Stellates interact and surround the hollow microvessels. Steatosis was induced by exogenous administration of fatty acids which could be prevented by co-administration of firsocostat. Administration of TGF-β resulted in an activated stellate cells phenotype which could be prevented by the co-administration of SB-431542. The model was implemented on a microtiter plate format comprising 64 chips which enabled the development of a fully automated, multiplexed fibrosis assay with a robust Z’ factor suitable for high-throughput applications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Liver physiology and pathology · Pancreatic function and diabetes · Liver Disease Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (69)
Show source-provided references
1. Liver and biliary system
2. In vitro models for non-alcoholic fatty liver disease: emerging platforms and their applications10.1016/j.isci.2021.103549 ↗
3. Preclinical models of non-alcoholic fatty liver disease10.1016/j.jhep.2017.10.031 ↗
4. The role of non-parenchymal liver cells in early hepatitis B virus and hepatitis C virus infection
5. Non-parenchymal cells and the extracellular matrix in hepatocellular carcinoma in non-alcoholic fatty liver disease10.3390/cancers15041308 ↗
6. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis10.1016/j.addr.2021.113869 ↗
7. Liver immunology and its role in inflammation and homeostasis10.1038/cmi.2016.3 ↗
8. A pathogenic role of non-parenchymal liver cells in alcohol-associated liver disease of infectious and non-infectious origin10.3390/biology12020255 ↗
9. Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis10.1097/MOL.0000000000000535 ↗
10. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease10.1038/srep25187 ↗
11. Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis10.3390/cells9040964 ↗
12. Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotype
13. A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates10.1038/s41598-021-01951-7 ↗
14. Human hepatic 3D spheroids as a model for steatosis and insulin resistance10.1038/s41598-018-32722-6 ↗
15. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury10.1007/s00204-017-2002-1 ↗
16. Functionality of primary hepatic non-parenchymal cells in a 3D spheroid model and contribution to acetaminophen hepatotoxicity10.1007/s00204-020-02682-w ↗
17. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation10.1038/nprot.2016.097 ↗
18. Long-term culture of genome-stable bipotent stem cells from adult human liver10.1016/j.cell.2014.11.050 ↗
19. Establishment of human fetal hepatocyte organoids and CRISPR–Cas9-based gene knockin and knockout in organoid cultures from human liver10.1038/s41596-020-00411-2 ↗
20. En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH10.1016/j.cell.2022.09.031 ↗
21. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids10.1016/j.cmet.2019.05.007 ↗
22. Scalable production of tissue-like vascularized liver organoids from human PSCs10.1038/s12276-023-01074-1 ↗
23. Journey of organ on a chip technology and its role in future healthcare scenario10.1016/j.apsadv.2022.100246 ↗
24. Organ-on-a-chip: recent breakthroughs and future prospects10.1186/s12938-020-0752-0 ↗
25. The relevance and potential roles of microphysiological systems in biology and medicine10.1177/1535370214542068 ↗
26. Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery10.3389/fphar.2023.1139229 ↗
27. Development of lumen-based perfusable 3D liver in vitro model using single-step bioprinting with composite bioinks10.1016/j.mtbio.2023.100723 ↗
28. Microneedle array facilitates hepatic sinusoid construction in a large-scale liver-acinus-chip microsystem10.1038/s41378-023-00544-w ↗
29. Mimicking liver sinusoidal structures and functions using a 3D-configured microfluidic chip10.1039/C6LC01374K ↗
30. In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed10.1007/s10456-022-09842-9 ↗
31. Integration of multiple readouts into the Z’ factor for assay quality assessment10.1177/1087057109351311 ↗
32. LABKIT: labeling and segmentation toolkit for big image data10.3389/fcomp.2022.777728 ↗
33. Phaseguides: a paradigm shift in microfluidic priming and emptying10.1039/c0lc00643b ↗
34. Cortical spheroid on perfusable microvascular network in a microfluidic device10.1371/journal.pone.0288025 ↗
35. Development of human-derived, three-dimensional respiratory epithelial tissue constructs with perfusable microvasculature on a high-throughput microfluidics screening platform10.1088/1758-5090/ac32a5 ↗
36. In vitro models of angiogenesis and vasculogenesis in fibrin gel10.1016/j.yexcr.2013.06.006 ↗
37. SB-431542 Is a potent and specific inhibitor of transforming growth factor-superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK710.1124/mol.62.1.65 ↗
38. The cell biology of the hepatocyte: a membrane trafficking machine10.1083/jcb.201903090 ↗
39. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease10.1007/s00018-018-2860-6 ↗
40. The different mechanisms of lipid accumulation in hepatocytes induced by oleic acid/palmitic acid and high-fat diet10.3390/molecules28186714 ↗
41. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)10.1080/13543784.2020.1668374 ↗
42. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease10.1053/j.gastro.2018.07.027 ↗
43. Activation of kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions10.3389/fcell.2023.1199519 ↗
44. Cellular and molecular mechanisms of fibrosis10.1002/path.2277 ↗
45. Mechanisms of hepatic stellate cell activation10.1038/nrgastro.2017.38 ↗
46. The role of CTGF in liver fibrosis induced in 3D human liver spheroids10.3390/cells12020302 ↗
47. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases10.1111/j.1478-3231.2008.01826.x ↗
48. A guide to the organ-on-a-chip10.1038/s43586-022-00118-6 ↗
49. High-throughput organ-on-chip platform with integrated programmable fluid flow and real-time sensing for complex tissue models in drug development workflows10.1039/D1LC00067E ↗
50. Operationalizing the use of biofabricated tissue models as preclinical screening platforms for drug discovery and development10.1177/24725552211030903 ↗
51. Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature10.1089/ten.tea.2008.0314 ↗
52. Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms10.1007/s10456-010-9194-9 ↗
53. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature10.1182/blood-2007-10-118273 ↗
54. Vascularized microfluidic organ-chips for drug screening, disease models and tissue engineering10.1016/j.copbio.2018.03.011 ↗
55. Microphysiological engineering of self-assembled and perfusable microvascular beds for the production of vascularized three-dimensional human microtissues10.1021/acsnano.9b00686 ↗
56. IFlowPlate—a customized 384-well plate for the culture of perfusable vascularized colon organoids10.1002/adma.202002974 ↗
57. Efficient hepatic differentiation of hydrogel microsphere-encapsulated human pluripotent stem cells for engineering prevascularized liver tissue10.1088/1758-5090/aca79b ↗
58. A fully defined matrix to support a pluripotent stem cell derived multi-cell-liver steatohepatitis and fibrosis model10.1016/j.biomaterials.2021.121006 ↗
59. Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting10.1073/pnas.1524510113 ↗
60. Basement membrane type IV collagen and laminin: an overview of their biology and value as fibrosis biomarkers of liver disease10.1002/ar.23567 ↗
61. Fibrin degradation enhances vascular smooth muscle cell proliferation and matrix deposition in fibrin-based tissue constructs fabricated in vitro10.1089/ten.tea.2009.0708 ↗
62. Intrahepatic fibrin(ogen) deposition drives liver regeneration after partial hepatectomy in mice and humans10.1182/blood-2018-08-869057 ↗
63. The liver, a functionalized vascular structure10.1038/s41598-020-73208-8 ↗
64. Liver sinusoidal endothelial cells—gatekeepers of hepatic immunity10.1038/s41575-018-0020-y ↗
65. Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat‐plate bioreactor10.1002/bit.1071 ↗
66. Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis10.1038/s41587-023-01680-4 ↗
67. Kupffer cells in non-alcoholic fatty liver disease: friend or foe?10.7150/ijbs.47143 ↗
68. Bioengineered multicellular liver microtissues for modeling advanced hepatic fibrosis driven through non-alcoholic fatty liver disease10.1002/smll.202007425 ↗
69. A microphysiological system for studying nonalcoholic steatohepatitis10.1002/hep4.1450 ↗